Cargando…

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early...

Descripción completa

Detalles Bibliográficos
Autores principales: van Heek, Lutz, Stuka, Colin, Kaul, Helen, Müller, Horst, Mettler, Jasmin, Hitz, Felicitas, Baues, Christian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, Dietlein, Markus, Voltin, Conrad-Amadeus, Kobe, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206242/
https://www.ncbi.nlm.nih.gov/pubmed/35717166
http://dx.doi.org/10.1186/s12885-022-09758-z
_version_ 1784729297533009920
author van Heek, Lutz
Stuka, Colin
Kaul, Helen
Müller, Horst
Mettler, Jasmin
Hitz, Felicitas
Baues, Christian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
Dietlein, Markus
Voltin, Conrad-Amadeus
Kobe, Carsten
author_facet van Heek, Lutz
Stuka, Colin
Kaul, Helen
Müller, Horst
Mettler, Jasmin
Hitz, Felicitas
Baues, Christian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
Dietlein, Markus
Voltin, Conrad-Amadeus
Kobe, Carsten
author_sort van Heek, Lutz
collection PubMed
description BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial. METHODS: (18)F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV(4.0,) SUV(41%) and SUV(140%L)), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy. RESULTS: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV(4.0) for MTV- calculation (AUC 0.69 [95% CI 0.55–0.83]) and for TLG-calculation (AUC 0.69 [0.55–0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV(140%L) AUCs of 0.66 [0.53–0.80] for MTV and 0.67 for TLG [0.54–0.81]) were observed, while with SUV(41%) an AUC of 0.61 [0.45–0.76] for MTV, and an AUC 0.64 [0.49–0.80]) for TLG were seen. CONCLUSIONS: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV(4.0) for MTV and TLG calculation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00736320.
format Online
Article
Text
id pubmed-9206242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92062422022-06-19 Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial van Heek, Lutz Stuka, Colin Kaul, Helen Müller, Horst Mettler, Jasmin Hitz, Felicitas Baues, Christian Fuchs, Michael Borchmann, Peter Engert, Andreas Dietlein, Markus Voltin, Conrad-Amadeus Kobe, Carsten BMC Cancer Research Article BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial. METHODS: (18)F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV(4.0,) SUV(41%) and SUV(140%L)), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy. RESULTS: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV(4.0) for MTV- calculation (AUC 0.69 [95% CI 0.55–0.83]) and for TLG-calculation (AUC 0.69 [0.55–0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV(140%L) AUCs of 0.66 [0.53–0.80] for MTV and 0.67 for TLG [0.54–0.81]) were observed, while with SUV(41%) an AUC of 0.61 [0.45–0.76] for MTV, and an AUC 0.64 [0.49–0.80]) for TLG were seen. CONCLUSIONS: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV(4.0) for MTV and TLG calculation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00736320. BioMed Central 2022-06-18 /pmc/articles/PMC9206242/ /pubmed/35717166 http://dx.doi.org/10.1186/s12885-022-09758-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
van Heek, Lutz
Stuka, Colin
Kaul, Helen
Müller, Horst
Mettler, Jasmin
Hitz, Felicitas
Baues, Christian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
Dietlein, Markus
Voltin, Conrad-Amadeus
Kobe, Carsten
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
title Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
title_full Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
title_fullStr Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
title_full_unstemmed Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
title_short Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
title_sort predictive value of baseline metabolic tumor volume in early-stage favorable hodgkin lymphoma – data from the prospective, multicenter phase iii hd16 trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206242/
https://www.ncbi.nlm.nih.gov/pubmed/35717166
http://dx.doi.org/10.1186/s12885-022-09758-z
work_keys_str_mv AT vanheeklutz predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT stukacolin predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT kaulhelen predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT mullerhorst predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT mettlerjasmin predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT hitzfelicitas predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT baueschristian predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT fuchsmichael predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT borchmannpeter predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT engertandreas predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT dietleinmarkus predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT voltinconradamadeus predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial
AT kobecarsten predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial